Search results
Results From The WOW.Com Content Network
September 3, 2024 at 7:32 AM. By Foo Yun Chee. BRUSSELS (Reuters) -U.S. gene sequencing company Illumina on Tuesday won its court fight against the European Union's investigation of its $7.1 ...
(Reuters) -Illumina's board has approved a spinoff of Grail, the gene sequencing machine maker said on Monday, as the deal to take the company back into its fold three years ago faced immense ...
The EU competition enforcer subsequently blocked the $7.1 billion deal in 2022 on concerns that Illumina would have an incentive to stop Grail's rivals from accessing its technology to develop ...
grail.com. GRAIL, Inc. is an American biotechnology company based in Menlo Park, California. It was previously a subsidiary of Illumina started as a startup seeking to develop an early cancer screening test for people who do not have symptoms. [3] Grail was spun-out from Illumina on June 24, 2024. Their liquid biopsy (also called multi-cancer ...
The U.S. life sciences company had completed its $7.1 billion takeover of Grail in August 2021, without securing the EU regulatory approval. The European Commission ordered Illumina last December ...
Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and ...
The European Union on Thursday ordered U.S. biotech giant Illumina to undo its $7.1 billion purchase of cancer-screening company Grail because it closed the deal without approval of regulators in ...
U.S. cancer diagnostic test maker Grail, which will list its shares on the Nasdaq on Tuesday after being spun out of Illumina, is betting that commercial partnerships with health systems ...